The effect of asymptomatic infection with HTLV-III on the response of anogenital warts to intralesional treatment with recombinant alpha 2 interferon.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D001005:Anus Neoplasms / Q000150:complications / Q000628:therapy; D003218:Condylomata Acuminata / Q000150:complications / Q000628:therapy*; D017977:Deltaretrovirus / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications / Q000628:therapy; D005834:Genital Neoplasms, Male / Q000150:complications / Q000628:therapy; D015483:HIV Antibodies; D006716:Homosexuality; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012192:Retroviridae Infections / Q000150:complications*; D012749:Sexually Transmitted Diseases / Q000150:complications / Q000628:therapy
D000914:Antibodies, Viral; D015483:HIV Antibodies; D007370:Interferon Type I; D011994:Recombinant Proteins